<DOC>
	<DOC>NCT02287857</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Domestic Tenofovir Disoproxil Fumarate Tablets in Chinese patients with hepatitis B ,compared with Tenofovir Disoproxil Fumarate Tablets of Gilead.</brief_summary>
	<brief_title>Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>The initial treatment of subjects diagnosed of HBeAg positive or negative chronic hepatitis B Aged 18 to 65 years old，male or female Patients with previously HBsAgpositive lasted for 6months at least：HBeAgpositive subjects, HBVDNA&gt; 105copies/ml； HBeAgnegative subjects, HBVDNA&gt; 104copies/ml. 2 times the upper normal limit (2 × ULN) ≤ alanine aminotransferase (ALT) ≤ 10 × ULN. Total serum bilirubin (TBIL) ≤ 2.5 × ULN. Prothrombin activity (PTA) ≥ 60% or prothrombin time prolonged than normal ≤ 3 seconds). WBC ≥ 3.5 × 109 / L, PLT ≥ 80 × 109 / L, serum albumin (ALB)≥ 35 g / L. Creatinine (Cr) ≤ 1× ULN，serum phosphate was normal. Patients signed an informed consent form and compliance was good. Patients were infected with other viruses as HAV, HCV, HEV, HIV etc. Patients with cirrhosis or liver cancer. Pregnant woman, lactating women . Patients with severe heart, kidney, endocrine hematopoietic system and neuropsychiatric diseases. Patients with metabolic or autoimmune diseases such as systemic lupus erythematosus. Patients allergic for study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>